These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 11301911)

  • 1. [Angiotensin converting enzyme inhibitors in the treatment of heart failure].
    Bettencourt P; Ferreira A
    Rev Port Cardiol; 2000 Dec; 19 Suppl 2():II51-6. PubMed ID: 11301911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA; Movahed A
    Rev Cardiovasc Med; 2005; 6(4):206-13. PubMed ID: 16379016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M; Solomon SD
    Curr Opin Cardiol; 2006 Jul; 21(4):268-72. PubMed ID: 16755193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
    Berger AK; Duval S; Manske C; Vazquez G; Barber C; Miller L; Luepker RV
    Am Heart J; 2007 Jun; 153(6):1064-73. PubMed ID: 17540211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [ACE inhibitor or ATII receptor blocker in heart failure and myocardial infarction?].
    Landmark K; Reikvam A
    Tidsskr Nor Laegeforen; 2005 Jan; 125(1):38-40. PubMed ID: 15643463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure: an observational study of treatment rates and clinical outcome.
    Gotsman I; Rubonivich S; Azaz-Livshits T
    Isr Med Assoc J; 2008 Mar; 10(3):214-8. PubMed ID: 18494235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of angiotensin-converting enzyme inhibitors and variations in cognitive performance among patients with heart failure.
    Zuccalà G; Onder G; Marzetti E; Monaco MR; Cesari M; Cocchi A; Carbonin P; Bernabei R;
    Eur Heart J; 2005 Feb; 26(3):226-33. PubMed ID: 15618043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are angiotensin-receptor blockers (ARBs) equivalent to or better than angiotensin-converting enzyme (ACE) inhibitors in the treatment of heart failure?
    Reigle J
    Crit Care Nurse; 2004 Dec; 24(6):67-9. PubMed ID: 15646090
    [No Abstract]   [Full Text] [Related]  

  • 10. Combination therapy with ACE inhibitors and angiotensin-receptor blockers in heart failure.
    Scow DT; Smith EG; Shaughnessy AF
    Am Fam Physician; 2003 Nov; 68(9):1795-8. PubMed ID: 14620599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The role of ACE inhibitors and angiotensin receptor blockers in the treatment and prevention of chronic heart failure].
    Kárpáti P
    Orv Hetil; 2005 May; 146(18):827-31. PubMed ID: 15926627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving rationale for angiotensin-converting enzyme inhibition in chronic heart failure.
    Banerjee A; Talreja A; Sonnenblick EH; LeJemtel TH
    Mt Sinai J Med; 2003 Sep; 70(4):225-31. PubMed ID: 12968195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role and optimal dosing of angiotensin-converting enzyme inhibitors in heart failure.
    Kazi D; Deswal A
    Cardiol Clin; 2008 Feb; 26(1):1-14, v. PubMed ID: 18312901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Angiotensin-converting enzyme inhibition and cardiovascular prevention: more than twenty years of clinical success].
    Borghi C; Cosentino E; De Sanctis D
    Ital Heart J Suppl; 2005 Dec; 6(12):769-79. PubMed ID: 16444921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction.
    Masoudi FA; Rathore SS; Wang Y; Havranek EP; Curtis JP; Foody JM; Krumholz HM
    Circulation; 2004 Aug; 110(6):724-31. PubMed ID: 15289383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of angiotensin-converting enzyme inhibitors (ACE i) on zinc metabolism in patients with heart failure.
    Trasobares E; Corbatón A; González-Estecha M; Lopez-Colón JL; Prats P; Olivan P; Sánchez JA; Arroyo M
    J Trace Elem Med Biol; 2007; 21 Suppl 1():53-5. PubMed ID: 18039498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-converting enzyme inhibitors (ACE) in congestive heart failure.
    Fukuyama O
    Arch Intern Med; 1991 Aug; 151(8):1669-70. PubMed ID: 1872676
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical studies on the therapy of heart failure using ACE-inhibitors and AT1-receptor blockers--does combination treatment make sense?
    Hennig L
    Clin Nephrol; 2002 Jul; 58 Suppl 1():S7-11. PubMed ID: 12227730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of angiotensin-converting enzyme inhibitors in the treatment of heart failure in the 21st century].
    Gibelin P
    Arch Mal Coeur Vaiss; 2002 Feb; 95 Spec 4(5 Spec 4):41-5. PubMed ID: 11933555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.